Jazz Pharma to acquire Celator in $1.5 billion cash deal

31 May 2016

Ireland-incorporated Jazz Pharmaceuticals (Nasdaq: JAZZ) today revealed a definitive agreement to acquire Celator Pharmaceuticals (Nasdaq: CPXX) for $30.25 per share in cash, or around $1.5 billion in total.

News of the deal, announced before markets opened, saw Celator’s shares rocket 71% to $29.96 by mid-morning in New York.

The deal comes at more than double Celator's current market capitalization of $740 million. It is the second M&A announcement this year by Jazz, which just recently closed the acquisition of France-based Alizé Pharma in a $20.5 million transaction. Also, in 2013, Jazz acquired Italian company Gentium, which develops treatments for rare diseases, in a deal valued at about $1 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK